Trasylol aprotinin regulatory update

EMA's CHMP recommended lifting the marketing suspension of Bayer's Trasylol aprotinin in the EU following a review of the Canadian BART trial. The review found that the data on which the suspension was based were "unreliable." The committee concluded that Trasylol's benefits outweigh its risks in patients undergoing isolated heart bypass surgery who are at high risk of major blood loss. ...